GKTRF yields 1.82% · JNJ yields 2.13%● Live data
📍 GKTRF pulled ahead of the other in Year 1
Combined, GKTRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GKTRF + JNJ for your $10,000?
GEK TERNA Holdings, Real Estate, Construction S.A., together with its subsidiaries, engages in the construction, real estate, mining, electricity, and concession businesses in Greece, the Balkans, the Middle East, Eastern Europe, the United States, and internationally. The company is involved in the construction of motorways, rail networks, buildings, hospitals, museums, industrial facilities, hydroelectric projects, dams, power plants, etc. for public and private sectors; and the financing, management, and commercial operation of concession projects, such as motorways and parking stations. It also develops and operates wind farms, hydroelectric projects, waste treatment and biogas production plants, and photovoltaic parks, as well as develops pumped storage and infrastructure projects. In addition, the company produces 895.3 MW of electric energy and trades in natural gas. Further, it engages in the acquisition, development, and exploitation of real estate properties, including business centers, industrial parks, entertainment parks, residential properties, hotels, etc.; production of quarry products; and exploitation of magnesite quarries. Additionally, the company operates thermal power plants with a total installed capacity of 147 MW and 435 MW in Viotia, Greece. GEK TERNA Holdings, Real Estate, Construction S.A. was formerly known as Ermis Real Estate Constructions Enterprises S.A. The company was founded in 1960 and is headquartered in Athens, Greece.
Full GKTRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.